

Hepatitis C Tracking Data

(FY2020 Appropriation Act - Public Act 67 of 2019)

March 1, 2020

Sec. 1878. By March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(b) The total cost of treatment.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.

(e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.



Hepatitis C Tracking Data

Section 1878 PA 67 of 2019

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

In Fiscal Year 2018-2019, a total of 720 people were treated through traditional Medicaid and 941 people were treated through the Healthy Michigan Plan. There were 1,624 unique individuals treated, some individuals' eligibility fluctuated between programs during this time period.

(b) The total cost of treatment.

In Fiscal Year 2018-2019, a total of \$79,851,414 was spent on drugs designed to cure Chronic Hepatitis C.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

In Fiscal Year 2018-2019, \$34,780,965 was spent on those treated through traditional Medicaid, while \$45,070,449 was spent on those treated through the Healthy Michigan Plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment and (e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.¹

To calculate the cure and reinfection rates for those receiving these treatments, practitioners who treated 1,624 patients with paid claims for these drugs from October 1, 2018 through September 30, 2019 were surveyed. Once at least 30% of the survey responses have been received, the Department of Health and Human Services will submit a revised report.

¹ At this time, surveys detailing the cure and reinfection rates broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment for Fiscal Year 2018-2019 have not been returned to the department but will be published once available.